Table 5.
Total and breakdown of average costs per patient (scenario using the indirect treatment comparison)
| RBZ BS TAE | AFL TAE | |
|---|---|---|
| Costs by category (JPY) | ||
| Drugs and administration | 3,012,571 | 3,651,654 |
| Monitoring | 107,460 | 107,370 |
| Adverse events | 2958 | 16,440 |
| Societal cost—daily care | 20,645,101 | 20,675,770 |
| Societal cost—physician visit | 223,479 | 223,621 |
| Total | 23,991,569 | 24,674,855 |
| Difference in costs by category (JPY) | ||
| Drugs and administration | – | − 639,084 |
| Monitoring | – | 90 |
| Adverse events | – | − 13,493 |
| Societal cost—daily care | – | − 30,669 |
| Societal cost—physician visit | – | − 142 |
| Total | – | − 683,286 |
AFL aflibercept, BS biosimilar, BSC best supportive care, JPY Japanese yen, RBZ ranibizumab, TAE treat-and-extend